Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed ...

The University at Albany and Virginia Commonwealth University were awarded a $6.5 million NIH grant to establish a federal ...

Turns out we have an answer: His name, per the Globe and Mail, is Dean Angelo. And yes, he's a bodybuilder and trainer. He's ...

His parents Stephen and Jenny have asked Sheffield Children's NHS Foundation Trust to approve the use of drug givinostat, ...

Data from the Phase Ia/b study demonstrated that SAT-3247 was well-tolerated and safe with a desirable PK profile.

BridgeBio said an experimental therapy for a rare form of muscular dystrophy succeeded in a key trial, potentially setting up ...

Sarepta stock crashed late Monday after the biotech company said two of its muscular dystrophy drugs failed their ...

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Martin Zubimendi will miss out, thus forcing Mikel Arteta into at least one change for the Champions League tie ...

El Paris Saint-Germain echará de menos a su delantero Désiré Doué al menos varias semanas después de sufrir un una lesión ...